This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Alzheimer Disease  • Neuropathology  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Markus Britschgi, PhD; Tony Wyss-Coray, PhD

Arch Neurol. 2009;66(2):(doi:10.1001/archneurol.2008.530).

Alzheimer disease (AD) has become one of the main health concerns for the elderly population in the United States. Current treatments target symptoms only, but several advanced clinical trials are testing new drugs that are potentially disease modifying. Because AD is still difficult to diagnose in its earliest stages and the disease process is estimated to start many years before current clinical diagnosis is made, accurate and simple diagnostic tools are urgently needed. We recently described a blood-based panel of secreted signaling proteins that distinguishes between blinded samples from patients with AD and control subjects with high accuracy. The same proteins also predicted progression to AD in preclinical patients with mild cognitive impairment several years before clinical diagnosis for AD was made. Herein, we describe these findings and discuss the potential for a more general application of our proteomic approach in understanding and diagnosing disease.

Author Affiliations: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California (Drs Britschgi and Wyss-Coray); and VA Palo Alto Health Care System, Palo Alto, California (Dr Wyss-Coray).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2009;66(2):151-152.
FULL TEXT